Dr Daniel Elger
e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system. The firm has two drugs in the clinic: ETS2101, which is in phase I trials for cancer; and ETS6103, which is in phase II trials for major depressive disorder. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.
e-therapeutics
Chief Financial Officer
Dr Liam Evans
Hypha collaborates with pharma/biotech and agrochemical groups in the following areas
1. Production of metabolites of clinical and preclinical stage compounds that are difficult to synthesise using metabolising microbes:
+ mg amounts for MetID, quantification standards
+ gram quantities for tox/pharmacological studies
+ includes glucuronides and chemically intractable hydroxyl derivatives
Our microbial biotransformation service is also used to improve PK/solubility in hit-to-lead compounds
2. Niche natural products hit-finding
Licensing access to Hypha's MycoDiverse natural products library.
+ Used by biotech and pharma to find hit compounds against "difficult-to-hit" targets
+ Molecular weight range mostly between 200 and 400 DA
+ 50% novelty
+ Exclusive rights to develop and commercialise
3. Fermentation and purification of small molecules for semi-synthetic lead optimisation
